Conversely, metabolism and nutrition disorders were the most commonly reported delayed irAEs with anti-CTLA-4 medications as opposed to anti-PD-1/anti-PD-L1 medications (ROR025 = 3.13). The gene discussed is CTLA4; the disease is nutritional disorder.